✦ LIBER ✦

A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma

✍ Scribed by Christian Wülfing; Jean-Pascal H. Machiels; Dirk J. Richel; Marc-Oliver Grimm; Uwe Treiber; Marco R. De Groot; Philippe Beuzeboc; Roma Parikh; Frank Pétavy; Iman A. El-Hariry

Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 188 KB
Volume: 115
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.24337

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Docetaxel plus epidoxorubicin as neoadju

Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast : A single-center, Phase II study

✍ Andrea de Matteis; Francesco Nuzzo; Giuseppe D'Aiuto; Vincenzo Labonia; Gabriell 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB 👁 1 views

## Abstract ## BACKGROUND The objective of this study was to test the activity and toxicity of epirubicin plus docetaxel as primary chemotherapy for women with large, operable (T2; > 3 cm) or locally advanced (Stage III) breast carcinoma, including patients with inflammatory breast carcinoma. ##

Weekly docetaxel with either gemcitabine

Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma : Phase II trials of the Minnie Pearl Cancer Research Network

✍ John D. Hainsworth; Howard A. Burris III; Frederic T. Billings III; James E. Bra 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 3 views